Premium
The temporary use of thrombopoietin‐receptor agonists may induce a prolonged remission in adult chronic immune thrombocytopenia. Results of a French observational study
Author(s) -
Mahévas Matthieu,
Fain Olivier,
Ebbo Mikael,
RoudotThoraval Françoise,
Limal Nicolas,
Khellaf Mehdi,
Schleinitz Nicolas,
Bierling Philippe,
Languille Laeticia,
Godeau Bertrand,
Michel Marc
Publication year - 2014
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.12888
Subject(s) - thrombopoietin , discontinuation , medicine , romiplostim , eltrombopag , immune thrombocytopenia , thrombopoietin receptor , gastroenterology , immunology , platelet , genetics , stem cell , haematopoiesis , biology
Summary Thrombopoietin‐receptor agonists (Tpo‐ RA s) are highly effective in immune thrombocytopenia ( ITP ). Recently, cases of durable remission after Tpo‐ RA discontinuation in adult ITP have been reported. We aimed to describe the subset of patients in whom transient Tpo‐ RA therapy may induce a durable response. We studied all adults with primary ITP treated with at least one Tpo‐ RA over a 5‐year period ( n = 54) and seen at one of three participating referral centres in France. Tpo‐ RA s were discontinued in 20 of 28 patients who achieved a complete response. We excluded six patients because a previous treatment at the start of Tpo‐ RA treatment may have interfered with the response. Overall, eight patients with chronic ITP showed a sustained response [median follow‐up: 13·5 months (range 5–27 months)]. We could not identify a predictive factor of sustained response. In conclusion, a substantial proportion of ITP patients receiving Tpo‐ RA s can maintain a durable response after treatment discontinuation.